Provider Briefing: The Dyanavel XR Shortage in 2026

The amphetamine medication shortage that began in October 2022 continues to affect patients and providers alike. For clinicians who prescribe Dyanavel XR (Amphetamine extended-release oral suspension and tablets, Tris Pharma), this article provides a comprehensive update on supply status, prescribing considerations, alternative therapies, and tools to support your patients.

Shortage Timeline: How We Got Here

The current stimulant shortage has its roots in several converging factors:

• October 2022: The FDA officially acknowledged shortages of amphetamine mixed salts (Adderall and generics). The shortage quickly expanded to affect other amphetamine-based products, including Dyanavel XR.
• 2023: The CDC issued a health advisory regarding the stimulant shortage's impact on ADHD patients. ASHP began tracking amphetamine extended-release products on its drug shortage database.
• 2024: The DEA transitioned to a semi-annual quota system for non-injectable controlled substances. During this transition, some manufacturers did not receive timely quota allocations, exacerbating supply constraints.
• Fall 2025: The DEA officially increased Aggregate Production Quotas (APQs) for amphetamine and methylphenidate. This was a significant step, but production ramp-up requires time.
• Early 2026: Supply is improving but remains inconsistent. Dyanavel XR, as a single-source brand product, continues to face availability challenges.

Prescribing Implications

Dyanavel XR occupies a specific niche in ADHD pharmacotherapy:

• It is one of the only extended-release amphetamine products available as an oral suspension, making it a critical option for pediatric patients and others who cannot swallow tablets or capsules.
• The tablet formulation (5 mg, 10 mg, 15 mg, 20 mg) offers once-daily dosing with a 3.2:1 ratio of d-amphetamine to l-amphetamine.
• It is not interchangeable on a mg-per-mg basis with Adderall XR or other mixed amphetamine salts.
• There is no FDA-approved generic version of Dyanavel XR.

When prescribing or renewing Dyanavel XR, consider proactively discussing availability with patients and having a contingency plan in place.

Current Availability Picture

Availability of Dyanavel XR varies significantly by:

• Geography: Some regions have more consistent supply than others.
• Pharmacy type: Independent and specialty pharmacies are more likely to stock or order Dyanavel XR than large chain pharmacies.
• Formulation: Tablets and oral suspension may have different availability patterns.

Real-time availability can be checked using Medfinder for Providers, which allows clinicians to search pharmacy inventory by medication and location.

Cost and Access Considerations

Cost remains a significant barrier for many patients:

• Cash price: $460–$590 per month for a 30-day supply of tablets.
• Insurance coverage: Many plans require prior authorization and may mandate step therapy (e.g., trial of generic Adderall XR or generic Vyvanse first). Some formularies do not cover Dyanavel XR at all.
• Manufacturer savings: The Tris Pharma Savings Card reduces out-of-pocket cost to as low as $25/month for commercially insured and cash-paying patients. Not available for government-insured patients. Activation at trissavingscard.com.
• Patient assistance: NeedyMeds and RxAssist maintain directories of patient assistance programs for stimulant medications.

When submitting prior authorizations, document the clinical rationale for Dyanavel XR specifically — for example, the need for a liquid formulation, previous treatment failures with alternatives, or the specific amphetamine enantiomer ratio.

Tools and Resources for Providers

Several resources can help you support patients who are struggling to find Dyanavel XR:

• Medfinder for Providers: Real-time pharmacy availability search. Direct patients here or use it in your workflow to identify pharmacies with stock before sending prescriptions.
• ASHP Drug Shortage Database: Tracks amphetamine extended-release shortage status and provides manufacturer updates.
• FDA Drug Shortage Database: Official shortage listings and estimated resolution dates.
• Tris Pharma Medical Information: Contact for product-specific clinical questions at dyanavelxr.com.

Alternative Therapies to Consider

When Dyanavel XR is unavailable, the following alternatives may be appropriate depending on clinical circumstances:

Amphetamine-Based Alternatives

• Adderall XR (Mixed Amphetamine Salts XR): Multiple generics available. Capsule form only. Different amphetamine salt ratio (3:1 d-amp to l-amp as mixed salts). Not directly interchangeable on mg-per-mg basis.
• Vyvanse (Lisdexamfetamine): Prodrug with smoother pharmacokinetic profile. Generic available since 2023. Available as capsule and chewable tablet. Up to 14-hour duration.
• Adzenys XR-ODT: Bioequivalent to Adderall XR in orally disintegrating tablet form. May serve patients needing a non-swallow formulation, though it is also brand-only.
• Mydayis: Triple-bead extended-release mixed amphetamine salts. Up to 16-hour duration. Approved for patients ≥13 years. Brand-only.

Non-Amphetamine Stimulant Alternatives

• Concerta / Generic Methylphenidate ER: Different mechanism. Good option if amphetamine class is not essential.
• Quillivant XR (Methylphenidate oral suspension): Liquid formulation for patients who need the oral suspension specifically. Also manufactured by Tris Pharma.

For a patient-facing overview of these alternatives, you can share our article on alternatives to Dyanavel XR.

Looking Ahead

Several developments may improve the Dyanavel XR supply picture in 2026 and beyond:

• Increased DEA quotas should allow Tris Pharma and other manufacturers to produce more amphetamine products.
• Ongoing FDA oversight of the stimulant shortage may lead to additional regulatory actions to ease supply constraints.
• New ADHD medications entering the market (e.g., Xelstrym transdermal dextroamphetamine patch) may help distribute demand across more products.

However, until a generic version of Dyanavel XR becomes available, single-source supply vulnerability will remain a concern.

Final Thoughts

The Dyanavel XR shortage requires proactive clinical management. By staying informed about supply dynamics, preparing contingency prescribing plans, and leveraging tools like Medfinder for Providers, clinicians can help minimize treatment disruptions for their patients.

For the patient perspective, see our patient shortage update. For guidance on helping patients locate their medication, see our provider's guide to helping patients find Dyanavel XR.